Registration Options

Activity Date: 04/17/2023

Session Time and Location

The live session is complete.

Session Summary

Prior to the presentation, breakfast will be served from 7:00-7:15 AM Eastern. The program should begin right at 7:15 AM Eastern; however, small delays are possible due to the meal. We thank you in advance for your patience.

New treatments for schizophrenia are just around the corner and their pharmacological properties bring into question the etiology of schizophrenia. Novel antipsychotic therapies without D2 receptor activity have significant implications for care, and if approved, will represent the "third-generation" of antipsychotic medications. Join Dr. Jonathan Meyer for a compelling symposium that will cover these recent advancements in our understanding of schizophrenia and how novel pharmacotherapies that act upstream of the dopamine receptors may prove effective at addressing current treatment limitations.

Certificate Instructions

1.   Complete the evaluation:  (free NEI Guest account required)

2.   Print your certificate

Questions? email or phone 888-535-5600

Faculty Information and Disclosures

Learning Objectives

  1. Explore the evolving understanding of the neurobiology of schizophrenia
  2. Differentiate the mechanisms of action of recently approved and in-development treatments for schizophrenia
  3. Implement novel treatments for schizophrenia into clinical practice as they become available to address residual symptoms, medication side effects, and treatment nonadherence

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support

This activity is supported by an unrestricted educational grant from Sunovion and Otsuka America Pharmaceutical, Inc.